![Michael D. Casey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael D. Casey
No más puestos en curso
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
M. Wilsey | M | 71 | 15 años | |
David Elkins | M | 55 | 6 años | |
Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 años |
Hans Lennart Rudolf Wigzell | M | 86 | 14 años | |
Matt Roden | M | 53 | 5 años | |
Terrence Blaschke | M | 81 | 18 años | |
David J. Ellis | M | - | 13 años | |
Katherine Reynolds Kelly | F | 48 | 5 años | |
Judy Joice | F | 67 | 17 años | |
P. Joseph Campisi | M | - | 5 años | |
Jeffrey Galik | M | - | 5 años | |
Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 años |
Wei Qi Lin | M | - | 16 años | |
Ann Li Lee | M | 63 | 6 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Mark Alles | M | 64 | 15 años | |
Paul Berns | M | 57 |
Bone Care International, Inc.
![]() Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI.
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 10 años |
Sol Barer | M | 76 | 25 años | |
Jacqualyn Fouse | M | 62 | 7 años | |
Robert Hugin | M | 69 | 19 años | |
J. Boyle | M | 70 | 3 años | |
Jonathan Biller | M | 61 | 8 años | |
Thomas A. Schreck | M | 67 | 7 años | |
Matt Hogan | M | 64 | 12 años | |
Christopher Garabedian | M | 57 | 5 años | |
Ross Taylor | M | 60 | 4 años | |
Vladimir Esteban Ostoich Campusano | M | 79 | 25 años | |
Michael E. Hart | M | - |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 años |
Thomas Daniel | M | 70 | 10 años | |
Randolph Steer | M | 74 | 5 años | |
Peter Kellogg | M | 67 | 5 años | |
John F. Glenn | M | 62 |
Cholestech Corp.
![]() Cholestech Corp. Medical SpecialtiesHealth Technology Cholestech Corp. provides diagnostic tools and information for risk assessment and therapeutic monitoring of heart disease, inflammatory disorders, and diabetes. It manufactures LDX System, multi-analytic testing system, and accessories to perform individual tests. The company was founded in 1988 and is headquartered in Hayward, CA. | 3 años |
Dennis Brown | M | 74 |
Matrix Pharmaceutical, Inc.
![]() Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | 14 años |
Michael Barrett | M | 81 |
Genetic Therapy, Inc.
![]() Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | 8 años |
William Goolsbee | M | 70 | 9 años | |
Leslie Hudson | M | 76 | 2 años | |
Perry Karsen | M | 69 | 9 años | |
Timothy J. Smith | M | - | - | |
Scott Smith | M | 61 | 10 años | |
Jean Liu | F | 55 | 13 años | |
Martin V. Mulroy | M | 63 | 16 años | |
Rupert Vessey | M | 59 | 4 años | |
Richard J. Bastiani | M | 81 | 23 años | |
Michael Perry | M | 64 |
Genetic Therapy, Inc.
![]() Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | 3 años |
William M. Wardell | M | 85 | 6 años | |
Brendan Delaney | M | 49 | 6 años | |
Michael Bonney | M | 65 | 4 años | |
James Ryaby | M | 65 | 15 años | |
Thomas Perone | M | 59 | 12 años | |
Vernon Edward Altman | M | 79 | - | |
Gerald F. Masoudi | M | 56 | 3 años | |
Julia Haller | M | 69 | - | |
James Caruso | M | 65 |
Bone Care International, Inc.
![]() Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI.
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 años |
Patrick E. Flanigan | M | - | - | |
Stephen Shrewsbury | M | 67 | 2 años | |
Michael Friedman | M | 80 | 8 años | |
Anthony Chase | M | 69 | - | |
Sandy Mahatme | M | 59 | 6 años | |
Amrita Sethi | F | - | - | |
Shirley J. Leow | M | - | - | |
Jay Backstrom | M | 69 | 11 años | |
Ben Price | M | 68 | 9 años | |
K. Michael Forrest | M | 80 | 5 años | |
Jay Shepard | M | 66 | - | |
Alberto R. Santa Ines | M | 76 | 15 años | |
David Clark | M | 56 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 años |
John Weiland | M | 68 | 1 años | |
Patricia Hemingway Hall | F | 71 | 1 años | |
James M. Pusey | M | 65 | 1 años | |
Paula V. Mendenhall | M | 80 | 7 años | |
Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 años |
Rodman L. Drake | M | 80 | 8 años | |
Peter D. O'Hanley | M | 73 | 5 años | |
John W. Jackson | M | 78 | 10 años | |
Lawrence V. Stein | M | 74 | 3 años | |
David C. Dreyer | M | 67 |
SICOR, Inc.
![]() SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | 7 años |
Robert Hershberg | M | 61 | 6 años | |
Simon Benito | M | 79 | 17 años | |
Steven C. Halladay | M | 76 | 4 años | |
Leslie M. Taeger | M | 73 | 14 años | |
James R. Glynn | M | 77 |
Matrix Pharmaceutical, Inc.
![]() Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | 2 años |
Richard Morgan | M | 79 | 29 años | |
Donald J. Abraham | M | - |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 10 años |
Michael Cannon | M | 78 |
SICOR, Inc.
![]() SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | 7 años |
Thomas R. Trotter | M | - | 8 años | |
Alan P. Timmins | M | 63 | 16 años | |
Carrie Cox | F | 66 | 10 años | |
James J. Loughlin | M | 81 | 12 años | |
David Ludvigson | M | 74 |
Matrix Pharmaceutical, Inc.
![]() Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | 2 años |
David Stout | M | 70 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 años |
Richard W. Barker | M | 75 | 7 años | |
Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 años |
Gilla Kaplan | M | 76 | 20 años | |
Timothy Patrick Lynch | M | 54 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 años |
Ernest Mario | M | 85 | 12 años | |
Denis Burger | M | 80 | 16 años | |
William Rastetter | M | 75 | 6 años | |
Jacquelyn Sumer | F | 46 | 1 años | |
Mark G. Edwards | M | 66 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 años |
Luke Seikkula | M | 60 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 años |
Barbara E. Baring | F | - |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 100 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Michael D. Casey
- Red Personal